Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 13, 2023 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche awarded WHO prequalification for the cobas® HPV test, increasing access to cervical cancer screening tools in low and lower-middle income countries

Every year, over 600,000 women worldwide are diagnosed with cervical cancer and over 340,000 die from this preventable disease, caused by infection with human papillomavirus (HPV). Nine out of 10...
June 09, 2023 08:45 ET | Source: F. Hoffmann-La Roche Ltd

New data show Roche’s subcutaneously administered crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal haemoglobinuria (PNH)

The COMMODORE 2 study demonstrated that subcutaneous crovalimab every four weeks was non-inferior to intravenous eculizumab every two weeks, with comparable safety, in people new to C5...
May 17, 2023 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis

Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS)...
May 09, 2023 01:00 ET | Source: F. Hoffmann-La Roche Ltd

FDA accepts application for Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)

Acceptance based on two phase III studies that demonstrated early and sustained vision improvement with Vabysmo, meeting primary endpoint of non-inferiority compared to afliberceptApplication was...
May 04, 2023 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche launches Institute of Human Biology to accelerate breakthroughs in R&D by unlocking the potential of human model systems

The Institute of Human Biology aims to better predict which drug candidates are safe and most effective in patients by evolving and increasing the use of human model systems. Human model systems are...
April 26, 2023 12:50 ET | Source: F. Hoffmann-La Roche Ltd

CHMP recommends EU approval of Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma

Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphomaThe recommendation is based on results from the...
April 26, 2023 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad-hoc-Mitteilung gemäss Art. 53 LR] Roche erzielt im ersten Quartal ein starkes Verkaufswachstum im Basisgeschäft beider Divisionen; Rückgang der Konzernverkäufe aufgrund der erwartungsgemäss geringeren Nachfrage nach COVID-19-Tests

Basel, 26. April 2023 Wie erwartet führt die stark rückläufige Nachfrage nach COVID-19-Tests zu einer Abnahme der Konzernverkäufe (-3%1 zu konstanten Wechselkursen [CER] und -7% in Schweizer...
April 26, 2023 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Annonce événementielle selon l’art. 53 RC] Roche annonce une forte croissance des ventes dans les activités de base de ses deux divisions au T1 ; le recul des ventes du Groupe est dû à la baisse attendue de la demande de tests COVID-19

Bâle, le 26 avril 2023 Comme attendu, la baisse significative de la demande de tests COVID-19 entraîne une diminution des ventes du Groupe (-3 %1 à taux de change constants [TCC] et -7 % en francs...
April 26, 2023 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests

Basel, 26 April 2023 As expected, significantly lower demand for COVID-19 tests leads to a decrease in Group sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this...
April 25, 2023 15:00 ET | Source: F. Hoffmann-La Roche Ltd

New Vabysmo data suggest greater retinal drying versus aflibercept in nAMD and DME

Post-hoc analyses from four phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular...